Hodgson Kevin, Palakkamanil Mathew M, Zhang Angela, Dyachok Oksana M, Smith Corey A, Nicolela Marcelo T, Chauhan Balwantray C, Shuba Lesya M
Dalhousie University, Faculty of Medicine, Halifax, NS, Canada.
University of Alberta, Department of Ophthalmology and Visual Sciences, Edmonton, AB, Canada.
Can J Ophthalmol. 2025 Aug;60(4):e566-e571. doi: 10.1016/j.jcjo.2025.01.015. Epub 2025 Feb 26.
To evaluate the effect of ginkgo biloba extract (GBE) on optical coherence tomography angiography (OCT-A) macula and peripapillary perfusion parameters among patients with treated early-to-moderate primary open-angle glaucoma.
Clinical trial.
Seventeen patients with early-to-moderate (≥10 dB MD) primary open-angle glaucoma were matched to 17 control patients based on age, sex, and glaucoma status. A total sample size of 34 was determined for effect size 0.5, alpha 0.05, power 0.81, and critical t = 2.03. Normality was confirmed using the Kolmogorov-Smirnov and Shapiro-Wilk tests.
The intervention was 120 mg oral GBE twice daily for 4 months. OCT-A scans (15° × 15°) of the macula and peripapillary retina were acquired, two-dimensional projection slab images of the superficial vascular complex were exported, and image analysis was performed. Student's t test was used to compare perfusion density between groups, and between baseline and follow-up for each group. The main outcomes were perfusion density of the superficial vascular complex of the macula and the peripapillary region.
Comparison between baseline and 4 months' supplementation with GBE revealed no significant change in perfusion density in the macular area, 0.32 (0.04) versus 0.30 (0.04); p = 0.17, and was significantly lower in the peripapillary area, 0.44 (0.05) versus 0.42 (0.04); p = 0.02. No differences were observed in the control group.
Four-month supplementation with GBE did not result in clinically significant improvement in macula or peripapillary perfusion density in patients with treated early-to-moderate primary open-angle glaucoma. Larger studies are needed to confirm an absence of neuroprotective effects of GBE.
评估银杏叶提取物(GBE)对接受治疗的早中期原发性开角型青光眼患者光学相干断层扫描血管造影(OCT-A)黄斑和视乳头周围灌注参数的影响。
临床试验。
17例早中期(平均缺损≥10 dB)原发性开角型青光眼患者根据年龄、性别和青光眼病情与17例对照患者进行匹配。根据效应量0.5、α 0.05、检验效能0.81和临界t值=2.03确定总样本量为34。使用柯尔莫哥洛夫-斯米尔诺夫检验和夏皮罗-威尔克检验确认数据的正态性。
干预措施为每日口服120 mg GBE,持续4个月。获取黄斑和视乳头周围视网膜的OCT-A扫描图像(15°×15°),导出浅表血管复合体的二维投影平板图像,并进行图像分析。采用学生t检验比较组间以及每组基线与随访之间的灌注密度。主要结局指标为黄斑和视乳头周围区域浅表血管复合体的灌注密度。
比较GBE补充剂服用基线和4个月时的情况,黄斑区灌注密度无显著变化,分别为0.32(0.04)和0.30(0.04);p = 0.17,而视乳头周围区域灌注密度显著降低,分别为0.44(0.05)和0.42(0.04);p = 0.02。对照组未观察到差异。
对于接受治疗的早中期原发性开角型青光眼患者,服用GBE 4个月并未使黄斑或视乳头周围灌注密度出现具有临床意义的改善。需要开展更大规模的研究来证实GBE不存在神经保护作用。